Table 7.
Differences and overlap between treatment and control groups for drug classes assessed for antinociceptive efficacy in rats (A) and mice (B), which correspond to the forest plots of Figures 3 and 4.
| A Drug Class |
Effect Size | % of treatment group with larger mean than control group | % overlap | N |
|---|---|---|---|---|
| NAAA inhibitor | 1.59 | 94.4 | 42.7 | 78 |
| Unknown mechanism of action | 1.50 | 93.3 | 45.3 | 32 |
| CB2 receptor agonist | 1.48 | 93.1 | 45.9 | 1671 |
| THC | 1.47 | 92.9 | 46.2 | 476 |
| CB1 receptor inverse agonist | 1.44 | 92.5 | 47.2 | 131 |
| PPAR-alpha agonist | 1.40 | 91.9 | 48.4 | 1105 |
| Nonselective cannabinoid receptor agonist | 1.37 | 91.5 | 49.3 | 1379 |
| Anandamide transport inhibitor | 1.32 | 90.7 | 50.9 | 497 |
| Monoacylglycerol lipase inhibitor | 1.31 | 90.5 | 51.2 | 151 |
| FAAH inhibitor | 1.21 | 88.7 | 54.5 | 1270 |
| CB1 receptor agonist | 1.18 | 88.1 | 55.5 | 2021 |
| CBD | 1.12 | 86.9 | 57.5 | 383 |
| CB2 receptor inverse agonist | 0.96 | 83.1 | 63.1 | 8 |
| FABP inhibitor | 0.87 | 80.8 | 66.4 | 12 |
| Hemp oil | 0.09 | 53.6 | 96.4 | 12 |
| GPR55 agonist | −0.38 | 35.2 | 84.9 | 8 |
| PPAR-gamma antagonist | −0.72 | 23.6 | 71.9 | 26 |
| B Drug Class |
Effect Size | % of treatment group with larger mean than control group | % overlap | N |
|---|---|---|---|---|
| FAAH inhibitor/TRPA1 agonist | 3.52 | 100 | 7.84 | 24 |
| NAAA inhibitor | 3.23 | 99.9 | 10.6 | 110 |
| CB1 receptor inverse agonist | 2.69 | 99.6 | 17.9 | 66 |
| PPAR-alpha agonist | 2.60 | 99.5 | 19.4 | 508 |
| Diacylglycerol lipase inhibitor | 1.83 | 96.6 | 36 | 138 |
| FAAH inhibitor | 1.56 | 94.1 | 43.5 | 1058 |
| Unknown mechanism of action | 1.56 | 94.1 | 43.5 | 183 |
| Monoacylglycerol lipase inhibitor | 1.53 | 93.7 | 44.4 | 457 |
| Dual FAAH/MGL inhibitor | 1.42 | 92.2 | 47.8 | 84 |
| THC | 1.39 | 91.8 | 48.7 | 283 |
| CB1 receptor agonist | 1.38 | 91.6 | 49 | 887 |
| CB1 receptor PAM | 1.08 | 86 | 58.9 | 61 |
| CB2 receptor inverse agonist | 1.05 | 85.3 | 60 | 48 |
| CBD | 1.05 | 85.3 | 60 | 230 |
| Nonselective cannabinoid receptor agonist | 1.03 | 84.8 | 60.7 | 815 |
| CB2 receptor agonist | 1.03 | 84.8 | 60.7 | 1448 |
| Anandamide transport inhibitor | 0.82 | 79.4 | 68.2 | 146 |
| FABP inhibitor | 0.65 | 74.2 | 74.5 | 252 |
| ABHD6 inhibitor | 0.27 | 60.6 | 89.3 | 33 |
| FAAH inhibitor/TRPV1 agonist | −0.39 | 34.8 | 84.5 | 45 |
N, number of animals (Magnusson, 2020).
ABHD6, abhydrolase domain containing 6; CB2, cannabinoid type 2; CBD, cannabidiol; FAAH, fatty acid amide hydrolase; FABP, fatty acid-binding protein; MGL, monoacylglycerol lipase; NAAA, N-acylethanolamine-hydrolysing acid amidase; PAM, positive allosteric modulator; PPAR, peroxisome proliferator-activated receptor; TRPV1, transient receptor potential vanilloid receptor 1; THC, delta-9-tetrahydrocannabinol.